^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Melanoma

Related cancers:
9h
Enrollment closed • Enrollment change • Metastases
|
cyclophosphamide • fludarabine IV • OBX-115 • acetazolamide
9h
Enrollment open • Metastases
|
LGALS3 (Galectin 3)
|
Keytruda (pembrolizumab) • GB1211
13h
Transcriptomics analysis of LINC02202/XBP1 axis in melanoma: Implications for drug targeting and PD-1 monoclonal antibody efficacy. (PubMed, J Cell Mol Med)
Our findings shed light on the impact of LINC02202/XBP1 on the phenotype and function of malignant melanoma cells. Furthermore, this study provides a theoretical foundation for the development of novel immunotherapy strategies for malignant melanoma.
Journal • PD(L)-1 Biomarker • IO biomarker
|
XBP1 (X-box-binding protein 1) • MIR526B (MicroRNA 526b)
13h
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial. (PubMed, Nat Commun)
Cyclophosphamide (Cy) pre-treatment was also assessed...Multivariable Cox regression analysis of the intent-to-treat population identify vaccine arm (12MP + 6MHP+Cy) and patient sex (male) as the two significant predictors of enhanced survival. These findings support the value of adding cognate T cell help to cancer vaccines and also suggest a need to assess the impact of patient sex on immune therapy outcomes.
P2 data • Retrospective data • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
cyclophosphamide
14h
Inhibition of melanoma cell migration and invasion by natural coumarin auraptene through regulating EMT markers and reducing MMP-2 and MMP-9 activity. (PubMed, Eur J Pharmacol)
In addition, molecular docking verified the interactions between AUR and the active sites of wild-type and mutant MMP-2 and MMP-9. Accordingly, AUR could be considered as a potential natural agent with inhibitory effects on the migration and invasion of melanoma cells for future preclinical studies.
Journal
|
MMP2 (Matrix metallopeptidase 2) • FN1 (Fibronectin 1) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9)
15h
Malignant peripheral nerve sheath tumour with divergent epithelioid differentiation in a cat. (PubMed, J Comp Pathol)
Melanoma-associated antigen, desmin, α-smooth muscle actin, CD18, CD31, ionized calcium binding adapter molecule-1 and CK8/18 were not expressed, which helped differentiate the tumour from other feline spindloid cell neoplasms. These features are characteristic of divergent epithelioid differentiation of MPNST.
Journal
|
VIM (Vimentin) • CD31 (Platelet and endothelial cell adhesion molecule 1) • ITGB2 (Integrin Subunit Beta 2) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • GFAP (Glial Fibrillary Acidic Protein)
21h
Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. (PubMed, J Immunother Cancer)
Our proteomic analysis reveals an intra-tumoral population of SMA+CAFs enriched in pure DM. Additionally, increased expressions of immune checkpoints (LAG-3 and PD-1) in LA and within tumor were associated with poorer prognosis. These findings might have therapeutic implications and help guide treatment selection in addition to informing potential prognostic significance.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD163 (CD163 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD14 (CD14 Molecule) • CD68 (CD68 Molecule)
|
LAG3 expression • CTLA4 expression
21h
Ultraviolet Radiation Biological and Medical Implications. (PubMed, Curr Issues Mol Biol)
UV radiation plays a significant role in basal cell carcinoma (BCC) development by causing mutations in the Hedgehog (Hh) pathway, which dysregulates cell proliferation and survival. UV radiation can also induce the development of squamous cell carcinoma via mutations in the TP53 gene and upregulation of MMPs in the stroma layer of the skin.
Review • Journal
|
BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
TP53 mutation • BRAF mutation • NRAS mutation
22h
Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer. (PubMed, Cells)
We found that MC-SeCs (i) provide antifungal resistance with minimum inflammatory pathology through the activation of the tolerogenic aryl hydrocarbon receptor/indoleamine 2,3-dioxygenase pathway; (ii) do not affect tumor growth in vivo; and (iii) reduce the LLC cell metastatic cancer spread associated with restricted Vegfr2 expression in primary tumors. Our results point to the fine immunoregulation of SeCs in the relative absence of overt immunosuppression in both infection and cancer conditions, providing additional support for the potential therapeutic use of SeC grafts in human patients.
Preclinical • Journal • IO biomarker • Immunomodulating
|
KDR (Kinase insert domain receptor)
|
KDR expression
22h
Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics. (PubMed, Cells)
This was performed in the context of metastatic melanoma and the role of metastasectomy in the metastatic melanoma population. A comprehensive review of these molecular characteristics is presented with a focus on their prognosis and role in surgical metastasectomy.
Review • Journal • Surgery • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • MITF (Melanocyte Inducing Transcription Factor)
|
TP53 mutation • BRAF mutation • NRAS mutation • PTEN mutation • NF1 mutation
23h
Evaluation of the association between glutathione S-transferase polymorphisms and susceptibility to cutaneous melanoma: a systematic review and meta-analysis. (PubMed, Postepy Dermatol Alergol)
The current evidence is not sufficient to confirm or reject the intervention effect. Future research should consider gene-gene and gene-environment interactions, which could offer a more comprehensive understanding of the complex biology of melanoma.
Retrospective data • Review • Journal
|
GSTP1 (Glutathione S-transferase pi 1) • GSTM1 (Glutathione S-transferase mu 1) • GSTT1 (Glutathione S-transferase theta 1)
23h
Progerin Inhibits the Proliferation and Migration of Melanoma Cells by Regulating the Expression of Paxillin. (PubMed, Onco Targets Ther)
Mechanistic investigations further revealed that progerin achieves this inhibition of paxillin expression by upregulating miR-212. This study reveals that progerin may inhibit the migration and proliferation of melanoma cells through the miR-212/paxillin axis, which provides a new approach for the future treatment of this disease.
Journal
|
PXN (Paxillin)
1d
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. (PubMed, Mol Cancer)
The median OS from retreatment with RAF-2i was 15.5 months (11.1-30.8 m). Further prospective studies are needed to validate these results and expand targeted therapy options for RAF-aberrant cancers.
Journal • Pan tumor
|
BRAF (B-raf proto-oncogene)
1d
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (clinicaltrials.gov)
P1, N=230, Recruiting, Nested Therapeutics, Inc | Not yet recruiting --> Recruiting
Enrollment open
|
BRAF (B-raf proto-oncogene)
1d
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) (clinicaltrials.gov)
P1, N=79, Suspended, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase classification: P1a/1b --> P1 | N=37 --> 79 | Trial completion date: Mar 2023 --> Apr 2024 | Recruiting --> Suspended | Trial primary completion date: Sep 2022 --> Apr 2023
Phase classification • Enrollment change • Trial completion date • Trial suspension • Trial primary completion date • Metastases
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • NF1 (Neurofibromin 1)
|
NRAS mutation
|
FCN-159
1d
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (clinicaltrials.gov)
P1, N=30, Recruiting, Dana-Farber Cancer Institute | N=20 --> 30
Enrollment change • Combination therapy
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Mobista (CDX-301) • Neo Vax (NEO-PV-01)
1d
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver (clinicaltrials.gov)
P2, N=14, Active, not recruiting, Sidney Kimmel Cancer Center at Thomas Jefferson University | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date • Combination therapy • Metastases
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
1d
New P1 trial • Metastases
1d
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature (clinicaltrials.gov)
P=N/A, N=25, Not yet recruiting, Abramson Cancer Center at Penn Medicine
New trial • Checkpoint inhibition
1d
NCI-2018-01928: CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma (clinicaltrials.gov)
P1, N=7, Terminated, Roswell Park Cancer Institute | N=36 --> 7 | Trial completion date: Aug 2024 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Jan 2024; low accrual
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
2d
PROM2 overexpression induces metastatic potential through epithelial-to-mesenchymal transition and ferroptosis resistance in human cancers. (PubMed, Clin Transl Med)
Our results open the way for further studies using PROM2 as a bio-target in resort situations in human metastatic melanoma and also in other cancer types.
Journal • Metastases
|
PROM2 (Prominin 2)
2d
Regulatory T cells subgroups in the tumor microenvironment cannot be overlooked: Their involvement in prognosis and treatment strategy in melanoma. (PubMed, Environ Toxicol)
Tregs exert a critical role in immune suppression within the melanoma tumor microenvironment, revealing a potential molecular-level association with melanoma cells. Our innovative Treg-centered signature introduces a promising prognostic marker for melanoma, holding potential for future clinical prognostic assessments.
Journal • IO biomarker
|
CD4 (CD4 Molecule) • ITGB2 (Integrin Subunit Beta 2)
2d
The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases. (PubMed, Br J Pharmacol)
Currently, several agents have been reported to inhibit the activity of the AIM2 inflammasome and have the potential to be evaluated for use in clinical settings. In this review, we systemically elucidate the assembly, biological functions, regulation and mechanisms of the AIM2 inflammasome in cardio-cerebrovascular diseases and related metabolic diseases and outline the inhibitory agents of the AIM2 inflammasome as potential therapeutic drugs.
Review • Journal
|
IL18 (Interleukin 18) • AIM2 (Absent In Melanoma 2) • IL1B (Interleukin 1, beta) • CASP1 (Caspase 1)
2d
Single-cell RNA sequencing unveils tumor heterogeneity and immune microenvironment between subungual and plantar melanoma. (PubMed, Sci Rep)
The EPHA3-EFNA1 axis was expressed only in cancer-associated fibroblast (CAF) and melanocytes of PM, and the TIGIT-NECTIN2 axis was expressed in both AM subtypes of T/NK cells and melanocytes. Altogether, our study helps to elucidate the tumor heterogeneity in AM subpopulations and provides potential therapeutic targets for clinical research.
Journal • IO biomarker
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • EPHA3 (EPH receptor A3) • EFNA1 (Ephrin A1) • NECTIN2 (Nectin Cell Adhesion Molecule 2)
2d
MMP1, MMP9, MMP11 and MMP13 in melanoma and its metastasis - key points in understanding the mechanisms and celerity of tumor dissemination. (PubMed, Rom J Morphol Embryol)
This study emphasizes the roles of MMP1, MMP9, and MMP13 in the process of metastasis in melanoma and the opportunity to use them as therapeutic targets and surveillance molecules.
Journal
|
MMP9 (Matrix metallopeptidase 9) • MMP1 (Matrix metallopeptidase 1) • MMP11 (Matrix Metallopeptidase 11)
2d
Immunoexpression of Ki67, P16 and Beta-catenin in precursor lesions of cutaneous squamous cell carcinoma. (PubMed, Rom J Morphol Embryol)
The immunoreactivity to the investigated markers confirms the multistage skin carcinogenesis, and their involvement starting from the initiation phase of the cancer process. The importance of the studied markers in the evolution and prognosis of precancerous lesions of CSCC is also supported by the linear correlations revealed between the immunoexpressions of P16, Ki67 and the membranous immunoexpression of Beta-catenin in AK.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
CTNNB1 expression
2d
Trial completion • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)
3d
The role of GAPDH in the selective toxicity of CNP in melanoma cells. (PubMed, PLoS One)
We identified glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a target protein for CNP mediated thiol oxidation.
Journal
|
GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)
3d
Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12. (PubMed, J Immunother Cancer)
These findings highlight the potential of using Ellen-ΔORF8-tet-off-scIL12 as a novel VZV-based oncolytic virotherapy.
Journal
|
DUT (Deoxyuridine Triphosphatase) • NECTIN1 (Nectin Cell Adhesion Molecule 1)
3d
Melanoma-Modern Treatment for Metastatic Melanoma. (PubMed, Cancer J)
Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining length of therapy. Herein, we review the existing evidence supporting current standard immunotherapy regimens and discuss the clinical decision-making involved in treating patients with metastatic melanoma with checkpoint inhibitors.
Journal • Metastases
|
PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
|
Yervoy (ipilimumab)
3d
What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma? (PubMed, Cancer J)
Immune checkpoint inhibitors have become the preferred first-line standard-of-care treatment for patients with newly diagnosed metastatic disease in patients irrespective of BRAF mutational status. Given these developments, it is now less clear how to optimize the use of MAPK-targeted therapy regarding treatment setting and in sequence with immune checkpoint inhibitor.
Journal • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
3d
Updates in the Management of Uveal Melanoma. (PubMed, Cancer J)
The evolving landscape includes promising systemic treatments, such as tebentafusp, a novel immune-modulating bispecific fusion protein, and targeted therapies...Although recent progress has improved outcomes, ongoing research aims to address the unique challenges of UM and develop effective therapies, particularly for HLA-A*02:01-negative patients who represent a significant unmet medical need. This review comprehensively discusses the molecular characteristics of UM, risk stratification methods, and the current and future spectrum of regional and systemic therapeutic modalities.
Journal • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Kimmtrak (tebentafusp-tebn)
3d
Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care. (PubMed, Cancer J)
Therapies currently under investigation include, but are not limited to, novel immunotherapies, targeted therapies, tumor-infiltrating lymphocytes and other cellular therapies, oncolytic viral therapy and other injectables, and fecal microbiota transplant. In this review, we discuss the emerging treatment options for metastatic melanoma patients who have progressed on standard of care treatments.
Journal
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
3d
BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms. (PubMed, Am J Surg Pathol)
Expert melanoma pathologists in this study favored a diagnosis of ST in nearly half of the BAMS cases. There are BAMS cases that even experts cannot morphologically distinguish from true Spitz neoplasms.
Journal
|
BRAF (B-raf proto-oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
BRAF mutation • HRAS mutation
3d
The ω-3 polyunsaturated fatty acid docosahexaenoic acid enhances NK-cell antitumor effector functions. (PubMed, Cancer Immunol Res)
The PGC-1α inhibitor SR-18292 in vitro and NK cell-specific knockout of PGC-1α in mice reversed the antitumour effects of DHA. In summary, our findings broaden the current knowledge on how DHA supplementation protects against cancer growth from the perspective of immunomodulation by upregulating PGC-1α signalling-mediated mitochondrial OXPHOS activity in NK cells.
Journal
|
IFNG (Interferon, gamma) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
IFNG expression • LAMP1 expression
3d
Density of high endothelial venules and PDL-1 expression: relationship with tumor-infiltrating lymphocytes in primary cutaneous melanomas. (PubMed, An Acad Bras Cienc)
Our findings confirm the HEV role in the recruitment and facilitation of lymphocyte transport in cutaneous melanomas, where HEV density is strongly associated with the degree of TILs. Additionally, PDL-1 hyperexpression suggests a possible mechanism of tumor immune evasion, which may lead to inactivation and reduction of the tumor lymphocytes number.
Journal • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
3d
IL-12-Overexpressed Nanoparticles Suppress the Proliferation of Melanoma Through Inducing ICD and Activating DC, CD8+ T, and CD4+ T Cells. (PubMed, Int J Nanomedicine)
Interestingly, CPP-IL-12 treatment in local xenografts in the back of mice could effectively inhibit the growth of the distant untreated tumor. The novel CPP-IL-12 could overexpress IL-12 in melanoma cells and achieve immunotherapy to melanoma through inducing ICD, activating CD4+ T cell, and enhancing the function of tumor-reactive CD8+ T cells.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • HMGB1 (High Mobility Group Box 1) • GZMB (Granzyme B) • CALR (Calreticulin) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
3d
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse. (PubMed, Cell Rep Med)
In vivo BET inhibitor treatment delays tumor relapse in both melanoma and lung cancer. Our study suggests that combining standard of care therapy with BET inhibitors to eliminate residual persister cells is a promising therapeutic strategy.
Journal
|
GPX2 (Glutathione peroxidase 2 (gastrointestinal)) • ALDH3A1 (Aldehyde Dehydrogenase 3 Family Member A1)
3d
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy (clinicaltrials.gov)
P1, N=6, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=46 --> 6
Enrollment closed • Phase classification • Enrollment change • Checkpoint inhibition • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • LAG3 (Lymphocyte Activating 3)
|
bavunalimab (XmAb22841) • izuralimab (XmAb23104)
3d
Phase classification • Combination therapy • Checkpoint inhibition • Metastases
|
Keytruda (pembrolizumab) • S-531011
3d
SOCRATES: Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS (clinicaltrials.gov)
P2, N=180, Recruiting, Monash University | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
Trial completion date • Trial primary completion date • Checkpoint inhibition
4d
Fatostatin promotes anti-tumor immunity by reducing SREBP2 mediated cholesterol metabolism in tumor-infiltrating T lymphocytes. (PubMed, Eur J Pharmacol)
Nevertheless, this effect was impaired in immunodeficient nude mice, suggesting fatostatin's anti-tumor efficacy in transplanted tumors partly relies on T cell-mediated anti-tumor immunity. Our study highlights SREBP2-mediated cholesterol metabolism as a potential strategy for anti-tumor immunotherapy, and confirms fatostatin's promise in tumor immunotherapy.
Journal
|
CD8 (cluster of differentiation 8) • XBP1 (X-box-binding protein 1)